Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Companies warn investors that DOGE’s federal cuts might hurt business
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...
Managed Healthcare Executive21h
Medicaid Coverage of JAK Inhibitors for Alopecia is Limited | AAD 2025
Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...
360Dx28m
Neurology Blood Tests Primed to Improve Diagnosis, Management of Patients in Alzheimer's and Beyond
Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.
Investor's Business Daily on MSN21m
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Le Lézard2h
U.S. Medical Weight Loss Market Report 2025: The Impact of GLP-1s on Doctors, Hospitals, Clinics and Franchises - ResearchAndMarkets.com
The "U.S. Medical Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering. This report presents a complete picture of the medical weight loss market in the ...